BTCY BIOTRICITY INC.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1630113 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.7%
TTM net income YoY38.0%
TTM EPS YoY-4.9%
Revenue 3-yr CAGR14.9%
Net income 3-yr CAGR—
Margins
Gross margin81.8%
Operating margin9.7%
Net margin-16.7%
FCF margin—
EBITDA margin9.7%
Returns
ROE—
ROA-45.2%
ROIC (approx.)—
Asset turnover2.71x
Leverage & solvency
Liabilities / assets662.7%
Debt / equity—
Current ratio0.15x
Interest coverage0.49x
Cash quality & payout
Operating cash flow / net income0.09x
Accruals ratio-41.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $16.00M | $13.79M | $12.06M | $9.64M | $7.65M |
| Cost of revenue | $3.05M | $3.23M | $3.71M | $4.20M | $3.08M |
| Gross profit | $12.95M | $10.56M | $8.36M | $5.44M | $4.57M |
| R&D expense | $2.76M | $2.16M | $2.57M | $3.23M | $2.74M |
| SG&A expense | $8.49M | $10.86M | $14.61M | $17.62M | $18.56M |
| Operating income | $1.69M | -$2.45M | -$8.83M | -$15.41M | -$16.74M |
| Interest expense | $3.36M | $3.26M | $3.02M | $1.84M | $1.28M |
| Pretax income | -$2.40M | -$8.42M | -$14.09M | -$18.66M | -$29.13M |
| Net income | -$2.40M | -$8.42M | -$14.09M | -$18.66M | -$29.13M |
| EBITDA | $1.70M | -$2.44M | -$8.82M | -$15.40M | -$16.73M |
| EPS (basic) | -0.12 | -0.56 | -1.66 | -2.26 | -0.67 |
| EPS (diluted) | -0.12 | -0.56 | -1.66 | -2.26 | — |
| Weighted avg. shares (diluted) | 27.30M | 21.52M | 8.99M | 8.66M | — |
| Balance sheet | |||||
| Cash & equivalents | $149,789 | $365,145 | $786,060 | $570,460 | $12.07M |
| Receivables | $2.93M | $1.66M | $1.47M | $1.22M | $2.01M |
| Inventory | $1.34M | $1.56M | $1.88M | $2.34M | $842,924 |
| Current assets | $5.86M | $4.64M | $4.47M | $4.72M | $15.32M |
| PP&E, net | $3,646 | $9,599 | $15,552 | $21,506 | $21,506 |
| Total assets | $6.45M | $5.64M | $5.94M | $6.51M | $16.68M |
| Current liabilities | $37.14M | $20.64M | $22.70M | $11.16M | $4.87M |
| Total liabilities | $39.41M | $35.66M | $35.92M | $26.36M | $18.82M |
| Shareholders' equity | -$34.68M | -$32.01M | -$31.47M | -$19.85M | -$2.14M |
| Shares outstanding | 28.60M | 26.08M | 9.35M | 8.51M | 49.81M |
| Cash flow statement | |||||
| Operating cash flow | -$718,955 | -$2.38M | -$6.69M | -$13.55M | -$15.16M |
| Capital expenditure | — | — | — | — | $29,767 |
| Free cash flow | — | — | — | — | -$15.19M |
| Investing cash flow | — | — | — | — | -$29,767 |
| Financing cash flow | $557,736 | $1.93M | $6.74M | $2.00M | $25.17M |
| Depreciation & amortization | $5,953 | $5,953 | $5,953 | $5,953 | $2,308 |
| Stock-based compensation | $25,632 | $1.46M | $1.03M | $647,631 | $913,613 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.